Predictive Value of Protease-activated Receptor-2 (PAR ) in Cervical Cancer Metastasis

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2020 Dec 28

PMID 33369107

Citations 4

Authors

Shengnan He

Meiquan Xu

Zhen Xiong

Ye Hu

Qin Huo

Jingxiao Lu

Yuntao Lin

Lan Yang

Affiliations

Soon will be listed here.

Abstract

Metastasis is the primary cause of an unfavourable prognosis in patients with malignant cancer. Over the last decade, the role of proteinases in the tumour microenvironment has attracted increasing attention. As a sensor of proteinases, proteinase-activated receptor 2 (PAR ) plays crucial roles in the metastatic progression of cervical cancer. In the present study, the expression of PAR in multiple types of cancer was analysed by Gene Expression Profiling Interactive Analysis (GEPIA). Kaplan-Meier plotter was used to calculate the correlation between survival and the levels of PAR , Grb-associated binding protein 2(Gab2) and miR-125b. Immunohistochemistry (IHC) was performed to examine PAR expression in a tissue microarray (TMA) of CESCs. Empower Stats was used to assess the predictive value of PAR in the metastatic potential of CESC. We found that PAR up-regulation was observed in multiple types of cancer. Moreover, PAR expression was positively correlated with the clinicopathologic characteristics of CESC. miR-125b and its target Gab2, which are strongly associated with PAR -induced cell migration, are well-characterized as predictors of the prognostic value of CESC. Most importantly, the Cancer Genome Atlas (TCGA) data set analysis showed that the area under the curve (AUC) of the PAR model was significantly greater than that of the traditional model (0.833 vs 0.790, P < .05), demonstrating the predictive value of PAR in CESC metastasis. Our results suggest that PAR may serve as a prognostic factor for metastasis in CESC patients.

Citing Articles

Non-linear association between AKI alert detection rate by physicians and medical costs.

Ai H, Jiang E, Wang H, Yang Q, Jin Q, Wan L PLoS One. 2025; 20(2):e0314907.

PMID: 40009619 PMC: 11864515. DOI: 10.1371/journal.pone.0314907.

Bioinformatics and experimental insights into F2RL1 as a key biomarker in cervical cancer diagnosis and prognosis.

Dai Y, Li C, Cheng S, Wang H, Zhuang X Sci Rep. 2025; 15(1):5228.

PMID: 39939734 PMC: 11821865. DOI: 10.1038/s41598-025-89746-y.

Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy.

Huo H, Feng Y, Tang Q Cancer Chemother Pharmacol. 2024; 93(5):397-410.

PMID: 38172304 PMC: 11043148. DOI: 10.1007/s00280-023-04630-8.

The role of cellular proteostasis in antitumor immunity.

Mercier R, LaPointe P J Biol Chem. 2022; 298(5):101930.

PMID: 35421375 PMC: 9108985. DOI: 10.1016/j.jbc.2022.101930.

TMEM45A Affects Proliferation, Apoptosis, Epithelial-Mesenchymal Transition, Migration, Invasion and Cisplatin Resistance of HPV-Positive Cervical Cancer Cell Lines.

Liu Y, Liu L, Mou Z Biochem Genet. 2021; 60(1):173-190.

PMID: 34143331 DOI: 10.1007/s10528-021-10094-3.

References

Xiao Y, Humphries B, Yang C, Wang Z . MiR-205 Dysregulations in Breast Cancer: The Complexity and Opportunities. Noncoding RNA. 2019; 5(4). PMC: 6958506. DOI: 10.3390/ncrna5040053. View

de Albuquerque A, Kubisch I, Stolzel U, Ernst D, Boese-Landgraf J, Breier G . Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients. J Transl Med. 2012; 10:222. PMC: 3508882. DOI: 10.1186/1479-5876-10-222. View

Hugo de Almeida V, Santos Guimaraes I, Almendra L, Rondon A, Tilli T, de Melo A . Positive crosstalk between EGFR and the TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer. Oncotarget. 2018; 9(55):30594-30609. PMC: 6078136. DOI: 10.18632/oncotarget.25748. View

Wang X, Zhang Z, Pan L, Cao X, Xiao C . KRT19 and CEACAM5 mRNA-marked circulated tumor cells indicate unfavorable prognosis of breast cancer patients. Breast Cancer Res Treat. 2018; 174(2):375-385. DOI: 10.1007/s10549-018-05069-9. View

Ma L . MicroRNA and Metastasis. Adv Cancer Res. 2016; 132:165-207. DOI: 10.1016/bs.acr.2016.07.004. View

Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

Beauchemin N, Arabzadeh A . Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 2013; 32(3-4):643-71. DOI: 10.1007/s10555-013-9444-6. View

Ramachandran R, Noorbakhsh F, Defea K, Hollenberg M . Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov. 2012; 11(1):69-86. DOI: 10.1038/nrd3615. View

Su S, Li Y, Luo Y, Sheng Y, Su Y, Padia R . Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration. Oncogene. 2009; 28(34):3047-57. PMC: 2733915. DOI: 10.1038/onc.2009.163. View

10.

Adams S, Aydin I, Celebi J . GAB2--a scaffolding protein in cancer. Mol Cancer Res. 2012; 10(10):1265-70. PMC: 3810274. DOI: 10.1158/1541-7786.MCR-12-0352. View

11.

Ohta T, Shimizu K, Yi S, Takamura H, Amaya K, Kitagawa H . Protease-activated receptor-2 expression and the role of trypsin in cell proliferation in human pancreatic cancers. Int J Oncol. 2003; 23(1):61-6. View

12.

Matsumura T, Sugimachi K, Takahashi Y, Uchi R, Sawada G, Ueda M . Clinical significance of GAB2, a scaffolding/docking protein acting downstream of EGFR in human colorectal cancer. Ann Surg Oncol. 2014; 21 Suppl 4:S743-9. DOI: 10.1245/s10434-014-3889-x. View

13.

Coughlin S . Thrombin signalling and protease-activated receptors. Nature. 2000; 407(6801):258-64. DOI: 10.1038/35025229. View

14.

Ma Y, Bao-Han W, Lv X, Su Y, Zhao X, Yin Y . MicroRNA-34a mediates the autocrine signaling of PAR2-activating proteinase and its role in colonic cancer cell proliferation. PLoS One. 2013; 8(8):e72383. PMC: 3753253. DOI: 10.1371/journal.pone.0072383. View

15.

Sun C, Li S, Chen Z, Li G, Zhang Q, Li D . Expression and Prognosis Analyses of Runt-Related Transcription Factor Family in Human Leukemia. Mol Ther Oncolytics. 2019; 12:103-111. PMC: 6350111. DOI: 10.1016/j.omto.2018.12.008. View

16.

Chaffer C, Weinberg R . A perspective on cancer cell metastasis. Science. 2011; 331(6024):1559-64. DOI: 10.1126/science.1203543. View

17.

Sun C, Li S, Hu W, Zhang J, Zhou Q, Liu C . RETRACTED: Comprehensive Analysis of the Expression and Prognosis for E2Fs in Human Breast Cancer. Mol Ther. 2019; 27(6):1153-1165. PMC: 6554685. DOI: 10.1016/j.ymthe.2019.03.019. View

18.

Liang L, Wong C, Ying Q, Fan D, Huang S, Ding J . MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology. 2010; 52(5):1731-40. DOI: 10.1002/hep.23904. View

19.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

20.

Rong Y, Belozerov V, Tucker-Burden C, Chen G, Durden D, Olson J . Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res. 2009; 69(6):2540-9. PMC: 2759716. DOI: 10.1158/0008-5472.CAN-08-1547. View